Alto Neuroscience Total Long-Term Assets 2022-2025 | ANRO

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Alto Neuroscience total long-term assets from 2022 to 2025. Total long-term assets can be defined as the sum of all assets classified as non-current

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Alto Neuroscience total long-term assets from 2022 to 2025. Total long-term assets can be defined as the sum of all assets classified as non-current

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$214.8B
Amgen (AMGN)	$160.4B
Gilead Sciences (GILD)	$135.3B
Vertex Pharmaceuticals (VRTX)	$119B
Bristol Myers Squibb (BMY)	$97.8B
CSL (CSLLY)	$78.3B
GSK (GSK)	$74.7B
Regeneron Pharmaceuticals (REGN)	$59.4B
Alnylam Pharmaceuticals (ALNY)	$42.3B
Argenex SE (ARGX)	$35B
BioNTech SE (BNTX)	$26.7B
Royalty Pharma (RPRX)	$19.9B
Insmed (INSM)	$19.8B
Biogen (BIIB)	$18.9B
Illumina (ILMN)	$15.5B
Genmab (GNMSF)	$14.5B
Genmab (GMAB)	$14.1B
Incyte (INCY)	$13.3B
Moderna (MRNA)	$12.5B
Exelixis (EXEL)	$12.2B
BioMarin Pharmaceutical (BMRN)	$11.2B
Ascendis Pharma (ASND)	$10.8B
QIAGEN (QGEN)	$10.7B
Swedish Orphan Biovitrum (BIOVF)	$10.6B
Exact Sciences (EXAS)	$9.8B
Verona Pharma American Depositary Share (VRNA)	$8.9B
Bio-Techne Corp (TECH)	$8.4B
Blueprint Medicines (BPMC)	$8.3B
Roivant Sciences (ROIV)	$7.9B
Legend Biotech (LEGN)	$7.7B